MedAdvisor Limited (AU:MDR) has released an update.
MedAdvisor Limited has reported a 3.5% increase in operating revenue for the first quarter of FY25, reaching $26.3 million, bolstered by growth in the US market’s pharmaceutical programs. Despite a slight dip in gross profit due to product mix changes, the company remains optimistic about its self-funded Transformation 360 initiative, aimed at reducing costs and boosting innovation. MedAdvisor has also refinanced its debt facility at a lower interest rate, with expectations of a solid revenue pipeline ahead.
For further insights into AU:MDR stock, check out TipRanks’ Stock Analysis page.